EHJ-CVP Editor-in-Chief

#EHJPharmacotherapy Editor-in-Chief X account. Posts by Prof. @BiancaRoccaTwt and her team.
@ESC_Journals

#PharmaPulse #pharmacotherapy #cardiology #cardioed

[EHJ-CVP Editor-in-Chief @EditorEHJCVP]

🆕New in #EHJCVP💥
🫀💊Can DAPT be safely and effectively shortened after DCB-only PCI in ACS?

In a SWEDEHEART analysis🇸🇪, abbreviated DAPT was not associated with a significant difference in NACE vs standard DAPT at 1 year from discharge date. However, wide CIs mean clinically relevant harm cannot be excluded⚠️ More evidence needed🔎

🔗 https://t.co/NM3didOITW

@BiancaRoccaTwt @doreen_sy @Costa_F_8 @OtiliaTica1 @ESC_Lavinia @escardio @ESC_Journals @Massimi78530343

[Francesco Costa @Costa_F_8]

Excited to start this new journey with #EHJCVP under the new leadership of @EditorEHJCVP. Many innovations ahead !

[EHJ-CVP Editor-in-Chief @EditorEHJCVP]

🆕A new era for #EHJCVP➡️ With this first editorial, we are proud to welcome an international & multidisciplinary Board committed to innovation, diversity, patient-centred care🫀and rigorous science📚
Together, shaping the future of cardiovascular pharmacotherapy🌍💊
🔗https://t.co/nJ3tH2yFhL

[EHJ-CVP Editor-in-Chief @EditorEHJCVP]

@OtiliaTica1

[EHJ-CVP Editor-in-Chief @EditorEHJCVP]

📢The new #EHJCVP issue is now online💥the first under Editor-in-Chief Prof. Bianca Rocca & the new editorial board!✍🏼
From innovation in CV pharmacotherapy to research integrity and cutting-edge science across the field🔬the issue opens with an editorial from EiC, setting the tone for journal's direction➡️
🔗https://t.co/LBqzH6LHHp @BiancaRoccaTwt @doreen_sy @Massimi78530343 @Costa_F_8 @ESCardioNews @ESC_Journals

[Francesco Costa @Costa_F_8]

Very interesting format for publishing rapid and concise results in the realm of Cardiovascular Pharmacotherapy. Attractive for substudies or focused updates of time sensitive evidence.

[EHJ-CVP Editor-in-Chief @EditorEHJCVP]

📢New in EHJ-CVP: The journal introduces Rapid Communications📜: a new concise article format for focused clinical & translational research🚀
≤1000 words (excluding references), emphasis on methods/results, 1 figure/table, no abstract or supplementals.
Fast, focused, impactful science!🔬
🔗https://t.co/20aXWom6cO
@BiancaRoccaTwt @doreen_sy @OtiliaTica1 @Massimi78530343 @Costa_F_8 @ESC_Journals @ESCardioNews

[EHJ-CVP Editor-in-Chief @EditorEHJCVP]

🚨New in EHJ-CVP🚨
HFpEF and HFmrEF therapies continue to evolve rapidly💊
This pre-specified Bayesian analysis of FINEARTS-HF adds another layer to the finerenone story — strengthening the probability of benefit for reducing worsening HF events and CV death across the preserved EF spectrum.

How do you see Bayesian analyses influencing the way we interpret HF trials and future guideline adoption?📊

Read the article in EHJ-CVP:
🔗https://t.co/kaVHrtI8aa

[EHJ-CVP Editor-in-Chief @EditorEHJCVP]

Impressive quality of submitted science driving the growth of cardiovascular knowledge🚀5869 abstracts&549 clinical cases accepted for #ESCCongress Munich🇩🇪
A huge step forward for science & collaboration🔬
Programme now live—Spread the word
Programme is now available online https://t.co/QqbK3stnCT

@BiancaRoccaTwt @ESC_Journals @ESC_Camille @Massimi78530343 @doreen_sy @OtiliaTica1 @Costa_F_8

[EHJ-CVP Editor-in-Chief @EditorEHJCVP]

✨EHJ-CVP has a new face!
New editorial board, updated scope & broader vision in cardiovascular pharmacotherapy🫀💊 From drug safety to real-world & translational research🔬New topics are now welcome!
Explore & submit your🔝quality research👉 https://t.co/wZul38m4AF @ESCardioNews

[European Society of Cardiology @escardio]

The European Society of Cardiology is deeply saddened by the passing of Professor Eugene Braunwald, one of the most influential figures in the history of cardiovascular medicine, who died on 22 April 2026, aged 96.

“Professor Braunwald was the leading cardiologist of his time. His vision and innovation changed the trajectory of cardiovascular medicine. He had a rare ability to see what the field needed next, and then to build the science and rigorous evidence leading to better care. He set a standard for intellectual honesty and mentorship, giving generations of clinicians and researchers the confidence to aim higher.” Professor Thomas F. Lüscher, @ESC_President

Professor Braunwald’s work helped define how cardiovascular disease is understood and treated. His legacy endures in the patients whose lives have been saved by evidence-based cardiovascular care, and in the people he inspired to pursue medicine with integrity and purpose https://t.co/IUtVSlbzph

[EHJ-CVP Editor-in-Chief @EditorEHJCVP]

#NewInEHJ-CVP
Exciting developments in cardiovascular medicine 🚀
The manuscript “New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2025” highlights cutting-edge therapies shaping the future of patient care. From innovative drug classes to precision-based treatment approaches, the landscape is evolving rapidly.

A must-read for clinicians, researchers, and anyone passionate about advancing CV pharmacotherapy.
🔗 DOI: 10.1093/ehjcvp/pvag016

[Otilia Tica @OtiliaTica1]

Extended dual pathway inhibition (#Aspirin + #rivaroxaban) continues to show benefits in chronic coronary syndrome

🫀In this COMPASS sub study: reduces MACE & all-cause death , but increases bleeding risk.

👉 https://t.co/W5VgoY7aaG

#Cardiology #CVPharm

[EHJ-CVP Editor-in-Chief @EditorEHJCVP]

🚨New in EHJ-CVP: Extended aspirin + rivaroxaban reduce MACE & mortality in CCS—but at a bleeding cost⚖️
In COMPASS trial, the 2024 ESC criteria failed to discriminate risk for ischaemic events❗️
➡️ Similar net clinical benefit across risk groups
➡️ Rethink risk stratification? @BiancaRoccaTwt
https://t.co/3WAFfM9ISE

[EHJ-CVP Editor-in-Chief @EditorEHJCVP]

🚨New in EHJ-CVP: Extended aspirin + rivaroxaban reduce MACE & mortality in CCS—but at a bleeding cost⚖️
In COMPASS trial, the 2024 ESC criteria failed to discriminate risk for ischaemic events❗️
➡️ Similar net clinical benefit across risk groups
➡️ Rethink risk stratification? @BiancaRoccaTwt
https://t.co/3WAFfM9ISE

[EHJ-CVP Editor-in-Chief @EditorEHJCVP]

CKM syndrome links heart🫀kidneys💧& metabolism⚡️. Despite strong evidence, SGLT2i are underused❗️
Time to shift → proactive care: early screening 🔍, simple pathways and cross-specialty collaboration🤝
Read the last Multidisciplinary Expert Perspective @BiancaRoccaTwt https://t.co/9ckKXvSDFV

[EHJ-CVP Editor-in-Chief @EditorEHJCVP]

https://t.co/D4cSqJudiU @Costa_F_8 @OtiliaTica1 @Massimi78530343 @doreen_sy

[EHJ-CVP Editor-in-Chief @EditorEHJCVP]

🧪Research integrity is not optional—it’s the foundation of science.
Predatory journals, paper mills, and data “spin” are increasingly contaminating the literature, threatening reliability, honesty, and trust in research.
We all have a role to play📚 @escardio @BiancaRoccaTwt

[EHJ-CVP Editor-in-Chief @EditorEHJCVP]

Looking for the perfect treatment after successful atrial fibrillation ablation

[Mattia Galli @MattiaGalli10]

Can we drop oral anticoagulant therapy after successful atrial fibrillation ablation?
https://t.co/7R496VZNlt